Legend Biotech Corp
LEGN39.455USD
+1.965+5.24%
Cierre 07/09, 16:00（ET）Cotizaciones retrasadas 15 min
7.26BCap. mercado
PérdidaP/E TTM
Más Datos de Legend Biotech Corp Compañía
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Información de la empresa
Símbolo de cotizaciónLEGN
Nombre de la empresaLegend Biotech Corp
Fecha de salida a bolsaJun 04, 2020
Fundada en2015
Director ejecutivoDr. Ying Huang, Ph.D.
Número de empleados2600
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 04
Dirección2101 Cottontail Lane
CiudadSOMERSET
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal08873
Teléfono17328505598
Sitio Webhttps://investors.legendbiotech.com/
Símbolo de cotizaciónLEGN
Fecha de salida a bolsaJun 04, 2020
Fundada en2015
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
168.29M
86.28%
Europe
26.67M
13.67%
China
90.00K
0.05%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: hace 9 horas
Actualizado: hace 9 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
6.11%
Westfield Capital Management Company, L.P.
3.75%
T. Rowe Price Associates, Inc.
3.65%
HHLR Advisors, Ltd.
3.25%
Suvretta Capital Management, LLC
2.03%
Other
81.21%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
6.11%
Westfield Capital Management Company, L.P.
3.75%
T. Rowe Price Associates, Inc.
3.65%
HHLR Advisors, Ltd.
3.25%
Suvretta Capital Management, LLC
2.03%
Other
81.21%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
19.22%
Investment Advisor/Hedge Fund
18.32%
Hedge Fund
8.47%
Research Firm
1.51%
Corporation
1.22%
Venture Capital
0.50%
Bank and Trust
0.40%
Pension Fund
0.13%
Insurance Company
0.09%
Other
50.14%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
544
92.22M
50.04%
-25.07M
2025Q1
566
91.15M
49.68%
-26.78M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
2023Q3
468
90.50M
49.93%
-2.81M
2023Q2
459
88.99M
49.23%
+9.84M
2023Q1
421
72.14M
43.70%
-3.07M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
11.26M
6.11%
-452.89K
-3.87%
Mar 31, 2025
Westfield Capital Management Company, L.P.
6.92M
3.75%
+1.20M
+21.07%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.73M
3.65%
-78.41K
-1.15%
Mar 31, 2025
HHLR Advisors, Ltd.
5.98M
3.25%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
3.75M
2.03%
+253.73K
+7.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
1.69%
-148.24K
-4.55%
Mar 31, 2025
Braidwell LP
2.98M
1.62%
--
--
Mar 31, 2025
Invesco Advisers, Inc.
2.91M
1.58%
-373.35K
-11.36%
Mar 31, 2025
MFS Investment Management
2.27M
1.23%
+5.83K
+0.26%
Mar 31, 2025
Genscript Biotech Corp
2.25M
1.22%
--
--
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Harbor Health Care ETF
6.68%
Matthews Emerging Markets Discovery Active ETF
4.54%
Matthews Emerging Markets Sustainable Future Active ETF
4.48%
Global X Genomics & Biotechnology ETF
3.6%
Tema Oncology ETF
2.35%
Virtus LifeSci Biotech Products ETF
1.86%
KraneShares MSCI All China Health Care Index ETF
1.31%
iShares Biotechnology ETF
0.39%
ProShares Ultra Nasdaq Biotechnology
0.33%
iShares MSCI Emerging Markets Min Vol Factor ETF
0.29%
Ver más
Harbor Health Care ETF
Proporción6.68%
Matthews Emerging Markets Discovery Active ETF
Proporción4.54%
Matthews Emerging Markets Sustainable Future Active ETF
Proporción4.48%
Global X Genomics & Biotechnology ETF
Proporción3.6%
Tema Oncology ETF
Proporción2.35%
Virtus LifeSci Biotech Products ETF
Proporción1.86%
KraneShares MSCI All China Health Care Index ETF
Proporción1.31%
iShares Biotechnology ETF
Proporción0.39%
ProShares Ultra Nasdaq Biotechnology
Proporción0.33%
iShares MSCI Emerging Markets Min Vol Factor ETF
Proporción0.29%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
